Back to Atlas
CTransientStandard research/education caution
CMP-0296
Approved antimalarial; senolytic use not approved
Chloroquine
Senolytic-adjacent / Lysosomal stress
Context-dependent senolytic/autophagy-modulating research effect
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- 4-aminoquinoline
- Primary mechanism
- Lysosomal/autophagy disruption
- Primary market use
- Autophagy / senolytic research
Pharmacology
- Molecular weight (Da)
- 319.87
- Oral bioavailability
- Oral; high
- Half-life
- ~20-60 d
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/Preclinical
- Clinical status
- Approved antimalarial; senolytic use not approved
- Value-for-money score
- 2 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Long half-life and retinal/cardiac risks reduce practical value